Please join Dr. Kasraeian for this discussion on the “5 W’s” of Liquid Biopsy approaches, including Who, What, Why Where, and When to use liquid biopsy testing to improve management of prostate cancer.

 
Prostate cancer is a leading cause of cancer for men within the United States with estimates in 2020 of more than 191,000 new cases per year, and 30,000 deaths. The current gold standard for prostate cancer diagnosis – needle biopsy – often lacks a true reflection of the molecular profile of the tissue given sampling error and complex tumor heterogeneity. Further, the relative lack of PSA specificity for prostate cancer has led to over-diagnosis of clinically insignificant prostate cancer.